Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial

References

• Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940–1949. doi:10.1200/JCO.2005.02.6187
   PubMed Web of Science ®Google Scholar
• Swain SM, Tang G, Geyer CE, et al. Definitive results of a Phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013;31(26):3197–3204. doi:10.1200/JCO.2012.48.1275
   PubMed Web of Science ®Google Scholar
• Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053–2065. doi:10.1056/NEJMoa0909638
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686–3696. doi:10.1200/JCO.2005.10.517
   PubMed Web of Science ®Google Scholar
• Li J, Yu K, Pang D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial. J Clin Oncol. 2020;38(16):1774–1784. doi:10.1200/JCO.19.02474
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11–18. doi:10.1200/JCO.2011.35.4639
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi:10.1056/NEJMoa1612645
   PubMed Web of Science ®Google Scholar
• Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–213. doi:10.1200/JCO.19.00904
   PubMed Web of Science ®Google Scholar
• Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325(1):50–58. doi:10.1001/jama.2020.23370
   PubMed Web of Science ®Google Scholar
• Li JB, Lin ZC, Wong MCS, Wang HHX, Li M, Li S. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society. BMC Med. 2022;20(1):320. doi:10.1186/s12916-022-02516-9
   PubMed Web of Science ®Google Scholar
• Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455–465. doi:10.1038/nrclinonc.2010.82
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-The road to new treatment strategies. Lancet. 2017;389(10087):2430–2442. doi:10.1016/S0140-6736(16)32454-0
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125(1):145–156. doi:10.1007/s10549-010-1228-x
   PubMed Web of Science ®Google Scholar
• Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized Phase II and phase III trials. Clin Breast Cancer. 2000;1(1):32–40. doi:10.3816/CBC.2000.n.002
   PubMedGoogle Scholar
• Liutkauskiene S, Grizas S, Jureniene K, Suipyte J, Statnickaite A, Juozaityte E. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 2018;18(1):453. doi:10.1186/s12885-018-4365-y
   PubMedGoogle Scholar
• Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–5387. doi:10.1200/JCO.2006.06.5391
   PubMed Web of Science ®Google Scholar
• Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664–5671. doi:10.1200/JCO.2006.07.3916
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671. doi:10.1056/NEJMoa0707056
   PubMed Web of Science ®Google Scholar
• Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized Phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805–814. doi:10.1093/jnci/djn151
   PubMedGoogle Scholar
• Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor. 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877–3884. doi:10.1200/JCO.2010.28.5437
   PubMed Web of Science ®Google Scholar
• Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72–80. doi:10.1016/S1470-2045(12)70525-9
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, Piccart M. Adjuvant systemic therapy in breast cancer: quo vadis? Ann Oncol. 2015;26(8):1629–1634. doi:10.1093/annonc/mdv108
   PubMed Web of Science ®Google Scholar
• Moon YW, Park S, Sohn JH, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137(7):1123–1130. doi:10.1007/s00432-011-0976-2
   PubMed Web of Science ®Google Scholar
• Schreiber AR, Kagihara J, Eguchi M, et al. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022;191(2):389–399. doi:10.1007/s10549-021-06424-z
   PubMed Web of Science ®Google Scholar
• Petrelli F, Bertaglia V, Parati MC, et al. Adjuvant chemotherapy for resected triple negative breast cancer patients: a network meta-analysis. Breast. 2023;67:8–13. doi:10.1016/j.breast.2022.12.004
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN Guidelines: registered) breast cancer. Version 1; 2023:62. Available from: http://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed March 28, 2024.
   Google Scholar
• Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897–904. doi:10.1007/s00277-010-0956-7
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma K, Li J, et al. The clinical value of chemotherapy combined with capecitabine in triple-negative breast cancer-a meta-analysis. Front Pharmacol. 2021;12:771839. doi:10.3389/fphar.2021.771839
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi:10.1056/NEJMoa2112651
   PubMed Web of Science ®Google Scholar
• Cunha MT, Gouveia MC, Neto FL, et al. Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis. Br J Cancer. 2024;130(2):242–250. doi:10.1038/s41416-023-02501-w
   PubMed Web of Science ®Google Scholar